• In February 2026, BeOne Medicines AG reported that fourth-quarter 2025 revenue rose to US$1,498.17 million from US$1,127.82 million a year earlier, with net income improving to US$66.5 million from a US$151.88 million loss, and issued 2026 guidance targeting US$6.2–US$6.4 billion in revenue and US$700–US$800 million in GAAP operating income.
• The company’s transition from a full-year 2024 net loss of US$644.79 million to a 2025 net profit of US$286.93 million, alongside Brukinza’s emergence as the leading BTK inhibitor in chronic lymphocytic leukemia worldwide, underscores how its oncology franchise is reshaping its financial profile and competitive position.
• We’ll now examine how BeOne’s move to GAAP profitability and stronger 2026 guidance could reshape the existing investment narrative for the company.

Uncover the next big thing with 30 elite penny stocks that balance risk and reward.

BeOne Medicines Investment Narrative Recap

To own BeOne Medicines, you need to believe its transition to GAAP profitability and its oncology portfolio can support durable, diversified earnings beyond Brukinza. The latest results and 2026 guidance reinforce that story, but they do not remove the key short term tension: trial and regulatory milestones for pipeline assets as the main upside catalyst, versus ongoing single product concentration in CLL and competitive pricing pressure as the central risk.

The most relevant update here is BeOne’s new 2026 outlook targeting US$6.2–US$6.4 billion in revenue and US$700–US$800 million in GAAP operating income. This guidance sits against prior expectations for strong growth and could influence how quickly the market reassesses the risk that heavy reliance on Brukinza creates, especially as upcoming pivotal readouts and regulatory decisions test whether BeOne can broaden its profit base beyond CLL.

Yet behind the headline profitability, investors should also be aware that...

BeOne Medicines' narrative projects $7.6 billion revenue and $1.3 billion earnings by 2028. This requires 18.6% yearly revenue growth and about a $1.48 billion earnings increase from -$177.6 million today.

Uncover how BeOne Medicines' forecasts yield a $404.19 fair value, a 35% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already penciling in about US$9.6 billion of revenue and US$2.7 billion of earnings by 2028, which is far more ambitious than the consensus story around Brukinza concentration and pricing pressure. This new guidance could either strengthen that optimistic view or bring it into question, so it is worth weighing how your expectations compare with both narratives.

Explore 6 other fair value estimates on BeOne Medicines - why the stock might be worth 14% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your BeOne Medicines research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free BeOne Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BeOne Medicines' overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 47 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.